Injectable ball-in-ball composite microspheres for subcutaneous filling and preparation method thereof

Through the design of ball-pack-type composite microspheres, combined with regenerated and non-regenerated microspheres, the problem of immediate filling and long-lasting repair performance of subcutaneous fillers is solved, and the effective repair effect in subcutaneous tissue is achieved and improved Safety and controllability of injections.

CN118512649BActive Publication Date: 2024-11-08SICHUAN UNIV
View PDF 13 Cites 0 Cited by

Patent Information

Application Number
CN202410993553.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-07-24
Publication Date
2024-11-08
Estimated Expiration
2044-07-24

AI Technical Summary

Technical Problem

Existing subcutaneous fillers fail to take into account immediate filling performance and durable repair performance, resulting in deficiencies in improving soft tissue volume loss and wrinkle repair effects.

Method used

Using ball-pack-ball composite microspheres, composed of regenerated microspheres and non-regenerated filled polymer materials, a three-dimensional network structure is formed by cross-linking or photo-crosslinking to ensure that the microspheres provide immediate filling and long-term repair in the subcutaneous tissue. .

Benefits of technology

It realizes the effect of filling and long-term repair after injection, avoids adverse reactions such as inflammatory nodules or granuloma caused by permanent fillers, and improves the controllability and safety of injection by regulating the composition and structure of the microspheres. sex.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118512649B_ABST
    Figure CN118512649B_ABST
Patent Text Reader

Abstract

The present invention belongs to the field of compositions of polymer compounds, and provides injectable ball-in-ball composite microspheres for subcutaneous filling and a preparation method thereof. The ball-in-ball composite microspheres are composed of monodispersed regenerative microspheres and non-regenerative filling polymer materials, the non-regenerative filling polymer materials are formed by crosslinking non-regenerative polymers through a crosslinking agent or by photocrosslinking non-regenerative polymers, the regenerative microspheres can stimulate fibroblasts in the skin to synthesize collagen, the regenerative microspheres are dispersed in the three-dimensional network structure of the non-regenerative filling polymer materials to form ball-in-ball composite microspheres, and the same ball-in-ball composite microsphere contains multiple regenerative microspheres; the particle size of the ball-in-ball composite microspheres is 100-300 μm. The present invention simultaneously gives the ball-in-ball composite microspheres immediate filling performance and the performance of stimulating collagen regeneration, solving the problem that the filling effect and the lasting effect of the existing subcutaneous fillers cannot be achieved at the same time.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of polymer compound compositions and relates to injectable ball-in-ball composite microspheres for subcutaneous filling and a preparation method thereof. Background Art

[0002] Subdermal fillers are injectable products used in light medical aesthetics to repair soft tissue volume loss and deeper static wrinkles or folds. They have the advantages of simple repair operation, less trauma, short recovery time and obvious repair effect. At present, subdermal fillers on the market are mainly divided into two categories: regenerative fillers and non-regenerative fillers.

[0003] Regenerative fillers are also called collagen stimulators, including poly-L-lactic acid, polycaprolactone, etc. These fillers have biostimulatory properties and can stimulate fibroblasts in the skin to synthesize collagen to compensate for the collagen lost with age. The mechanism by which regenerative fillers stimulate collagen regeneration is foreign body reaction. After being injected into the subcutaneous tissue, these fillers are first wrapped by lymphocytes such as macrophages and giant cells. Then, under the action of transforming growth factor, fibroblasts migrate to the surface of giant cells and are stimulated to synthesize extracellular matrix collagen. Since the spherical structure is conducive to promoting cellular foreign body reaction, regenerative fillers are usually prepared in the form of microspheres. When used, the microspheres are dispersed in a carrier solution and then injected subcutaneously. The carrier solution is usually a solution of carboxymethyl cellulose and mannitol. However, when the carrier solution dispersed with microspheres is injected into the subcutaneous tissue, the carrier solution will be quickly absorbed by the skin, which will cause the immediate filling effect of the regenerative filler to be greatly weakened.

[0004] Non-regenerative fillers include hyaluronic acid, collagen, etc. These fillers have good viscoelasticity and can be injected even in large sizes. They have a certain volume and immediately play a supporting role after being injected into the subcutaneous tissue, filling the skin depressions and achieving a cosmetic effect. However, non-regenerative fillers degrade quickly. With the degradation and metabolism of non-regenerative fillers, their wrinkle-removing effect gradually disappears, and their maintenance time in the body is short, and the filling effect is not long-lasting.

[0005] Existing subdermal fillers cannot provide both immediate filling performance and lasting repair performance. Therefore, if existing subdermal fillers can be improved, based on the fact that the same filler can achieve immediate filling performance while stimulating collagen regeneration, it will have a positive significance for improving soft tissue volume loss and enhancing the repair effect of wrinkles and folds. Summary of the invention

[0006] In view of the problem that the filling effect and the lasting effect of the existing subcutaneous fillers cannot be achieved at the same time, the present invention provides an injectable ball-in-ball composite microsphere for subcutaneous filling and a preparation method thereof, so as to simultaneously give the ball-in-ball composite microsphere an immediate filling performance and a performance of stimulating collagen regeneration, thereby improving the repair effect of the existing subcutaneous fillers on soft tissue volume loss and wrinkles and folds.

[0007] The present invention combines different polymer compounds to form a polymer compound composition with a specific structural form to solve the problem that the existing subcutaneous fillers cannot achieve both filling effect and long-lasting effect. To achieve the above invention purpose, the technical solution adopted by the present invention is as follows:

[0008] Disclosed is an injectable ball-in-ball composite microsphere for subcutaneous filling. The ball-in-ball composite microsphere is composed of monodispersed regenerative microspheres and non-regenerative filling polymer materials. The non-regenerative filling polymer materials are formed by cross-linking non-regenerative polymers through a cross-linking agent or by photo-crosslinking non-regenerative polymers. The regenerative microspheres can stimulate fibroblasts in the skin to synthesize collagen. The regenerative microspheres are dispersed in the three-dimensional network structure of the non-regenerative filling polymer material to form ball-in-ball composite microspheres. A plurality of regenerative microspheres are contained in the same ball-in-ball composite microsphere. The diameter of the ball-in-ball composite microsphere is 100-300 μm, and the coefficient of variation of the diameter of the ball-in-ball composite microsphere does not exceed 5%.

[0009] In the technical solution of the composite microspheres, the material of the regenerated microspheres is the material of the existing regenerated filler. Furthermore, the material of the regenerated microspheres is polycaprolactone or poly-L-lactic acid.

[0010] In the technical solution of the above-mentioned composite microspheres, in order to prevent the regenerative microspheres from being phagocytosed by macrophages and clogging blood vessels, the diameter of the regenerative microspheres is 20-90 μm. In order to enable the regenerative microspheres to better stimulate the fibroblasts in the skin to synthesize collagen, the diameter of the regenerative microspheres is preferably 40-60 μm; the coefficient of variation of the diameter of the regenerative microspheres does not exceed 5%, preferably, the coefficient of variation of the diameter of the regenerative microspheres does not exceed 3%.

[0011] In the technical solution of the composite microspheres, the material of the non-regenerative polymer is the material of the existing non-regenerative filler. Furthermore, the non-regenerative polymer is hyaluronic acid, methacryloyl hyaluronic acid or collagen.

[0012] In the technical solution of the above composite microspheres, in the ball-in-ball type composite microspheres, the mass ratio of the regenerated microspheres to the non-regenerated filling polymer material is 1:(4-8).

[0013] In the technical solution of the composite microspheres, when the non-renewable filling polymer material is formed by cross-linking the non-renewable polymer with a cross-linking agent, the non-renewable filling polymer material is preferably formed by cross-linking the non-renewable polymer and the cross-linking agent at a mass ratio of 1: (0.005-0.02). When the non-renewable filling polymer material is formed by photo-cross-linking the non-renewable polymer, the non-renewable polymer contains a photo-cross-linking group, and the non-renewable polymer is cross-linked by light to form the non-renewable filling polymer material.

[0014] In the above technical solution of composite microspheres, the coefficient of variation of the diameter of the ball-in-ball composite microspheres is preferably no more than 3%.

[0015] The present invention also provides a method for preparing the injectable ball-in-ball composite microspheres for subcutaneous filling, comprising the following steps:

[0016] (1) Preparation of internal phase fluid, external phase fluid and collection fluid

[0017] Preparation of internal phase fluid: dissolving non-regenerative polymer and cross-linking agent in aqueous solvent, adding monodisperse regenerative microspheres, fully dispersing to obtain internal phase fluid, wherein the mass ratio of aqueous solvent, non-regenerative polymer, cross-linking agent and regenerative microspheres in the internal phase fluid is 1: (0.02-0.05): (0.002-0.005): (0.002-0.008); or, dissolving non-regenerative polymer and photoinitiator in aqueous solvent, adding monodisperse regenerative microspheres, fully dispersing to obtain internal phase fluid, wherein the mass ratio of aqueous solvent, photoinitiator and regenerative microspheres in the internal phase fluid is 1: (0.001-0.003): (0.002-0.008);

[0018] Prepare the external phase fluid: dissolve the oil-soluble surfactant in the oily solvent to obtain the external phase fluid, in which the mass ratio of the oily solvent to the oil-soluble surfactant is 1:(0.04-0.08); or, dissolve the oil-soluble surfactant and the activator in the oily solvent to obtain the external phase fluid, in which the mass ratio of the oily solvent to the oil-soluble surfactant and the activator is 1:(0.04-0.08):(0.001-0.005);

[0019] Prepare the collecting fluid: the collecting fluid is the same as the external phase fluid;

[0020] (2) Preparation of ball-in-ball composite microspheres

[0021] The inner phase fluid is injected into the injection tube of the microfluidic device, and the outer phase fluid is injected into the collection tube of the microfluidic device to form a monodisperse oil-in-water-in-microsphere emulsion in the collection tube. The oil-in-water-in-microsphere emulsion is collected with a collecting liquid, and conditions are applied to cause a cross-linking reaction of the non-regenerative polymer in the oil-in-water-in-microsphere emulsion to solidify the oil-in-water-in-microsphere emulsion. The solidified microspheres are washed with anhydrous ethanol and dried to obtain ball-in-ball composite microspheres.

[0022] In the technical scheme of the above preparation method, the non-regenerative polymer is hyaluronic acid, methacryloyl hyaluronic acid or collagen; the cross-linking agent is adipic acid dihydrazide, 1,4-butanediol diglycidyl ether or glutaraldehyde. When the non-regenerative polymer is hyaluronic acid and the cross-linking agent is adipic acid dihydrazide, or when the non-regenerative polymer is collagen, the external phase fluid and the collection liquid contain the activator 1-ethyl-(3-dimethylaminopropyl) carbodiimide. When the non-regenerative polymer is methacryloyl hyaluronic acid, the internal phase fluid contains a photoinitiator, and in step (2), light of an appropriate wavelength is applied to initiate photo-cross-linking of the methacryloyl hyaluronic acid.

[0023] In the technical scheme of the above preparation method, the oil-soluble surfactant is polyricinoleic acid glyceride, oleic acid dianhydrous ethanolamide, T154, Span20, Span40, Span60, Span80 or Tween85.

[0024] In the technical solution of the above preparation method, the oily solvent is n-octanol or soybean oil.

[0025] In the technical solution of the above preparation method, the drying method adopted in step (2) can be drying, air drying or freeze drying.

[0026] In step (2) of the technical solution of the above-mentioned preparation method, the size of the prepared oil-in-water-in-microsphere emulsion droplets can be adjusted by adjusting the flow rate of the external phase fluid and the internal phase fluid, as well as the channel size of the microfluidic device. By adjusting the size of the oil-in-water-in-microsphere emulsion droplets, the size of the ball-in-ball composite microsphere can be adjusted. Preferably, in step (2), the volume flow ratio of the external phase fluid to the internal phase fluid is controlled to be (10~40):1. Furthermore, it is preferred to control the inner diameter of the outlet of the injection tube of the microfluidic device (i.e., the cone mouth inner diameter of the injection tube) to be 200~300 μm, and the inner diameter of the collection tube to be 500~700 μm. Under the conditions of the inner diameter of the outlet of the injection tube and the inner diameter of the collection tube, the flow rate of the internal phase fluid can be controlled to be 1~10 μL / min, and the flow rate of the external phase fluid can be controlled to be 40~150 μL / min.

[0027] In step (2) of the technical solution of the above preparation method, the injection tube of the microfluidic device is coaxially arranged with the collection tube, and the inner diameter of the outlet of the injection tube is 200-300 μm. A feasible structure of the microfluidic device is as follows Figure 1 As shown, it includes an injection tube, a connecting tube and a collecting tube, which are used in conjunction with an injection pump; the injection tube is made of a cylindrical glass capillary, and its tail is pulled into a cone shape; the collecting tube is a cylindrical glass capillary; the connecting tube is a square glass tube, and a square through hole is arranged in the center of the square glass capillary; the tail of the injection tube is inserted into the head of the collecting tube and connected through the connecting tube; the injection tube, the connecting tube and the collecting tube are coaxially arranged.

[0028] In step (2) of the technical solution of the above preparation method, the time of the cross-linking reaction is affected by the droplet size of the oil-in-water-in-microsphere emulsion. As the droplet size of the oil-in-water-in-microsphere emulsion increases, the time of the cross-linking reaction increases. Generally, the time of the cross-linking reaction is controlled to be at least 24 hours, for example, the time of the cross-linking reaction can be controlled to be 24 to 48 hours.

[0029] In the technical scheme of the above preparation method, the mechanical properties of the ball-in-ball composite microsphere can be adjusted by adjusting the content of the regenerative microsphere in the internal phase fluid. At the same time, the regeneration performance and degradation performance of the ball-in-ball composite microsphere can be adjusted by adjusting the content of the regenerative microsphere, the content of the crosslinking agent and the crosslinking time in the internal phase fluid.

[0030] In the technical solution of the above preparation method, the regenerative microspheres are preferably prepared by microfluidic technology.

[0031] The design concept of the ball-in-ball composite microsphere of the present invention is mainly as follows:

[0032] The regenerative microspheres are dispersed in the three-dimensional network structure of the non-regenerative filling polymer material to form a ball-in-ball composite microsphere, so that the same ball-in-ball composite microsphere contains multiple regenerative microspheres. Non-regenerative filling polymer materials, such as hyaluronic acid, collagen, etc., although they have good viscoelasticity and excellent biocompatibility, they have a fast degradation rate and poor mechanical strength. While regenerative microspheres, such as poly-L-lactic acid microspheres, polycaprolactone microspheres, etc., have the effect of stimulating collagen regeneration, they have poor elasticity and poor immediate filling performance. The present invention organically combines these two types of materials, and the regenerative microspheres are dispersed in the three-dimensional network structure of the non-regenerative filling polymer material. On the one hand, due to the encapsulation of the elastic non-regenerative filling polymer material, the ball-in-ball composite microsphere has good elasticity, and after being injected into the subcutaneous tissue, it can provide volume support and play an immediate filling role. On the other hand, as the non-regenerative filling polymer material encapsulating the regenerative microspheres gradually degrades, the regenerative microspheres can be exposed and released, and the regenerative microspheres can stimulate the fibroblasts in the skin to synthesize collagen, playing a role in long-term repair. In addition, by encapsulating the non-regenerative microspheres with poor elasticity and high hardness in the non-regenerative filling polymer material with excellent elasticity, the ball-in-ball composite microspheres can be given good compressibility and resilience, and the external particle size of the ball-in-ball composite microspheres can be unified. Good compressibility and resilience are conducive to the ball-in-ball composite microspheres being easy to inject and not prone to clogging. The uniform size can reduce the interruption of the particle extrusion process during injection, making it easier to better grasp the appropriate injection force and position.

[0033] Compared with the prior art, the technical solution of the present invention produces the following beneficial technical effects:

[0034] 1. The injectable ball-in-ball composite microsphere for subcutaneous filling provided by the present invention is composed of monodispersed regenerative microspheres and non-regenerative filling polymer materials, the non-regenerative filling polymer materials are formed by cross-linking non-regenerative polymers through a cross-linking agent, the regenerative microspheres can stimulate fibroblasts in the skin to synthesize collagen, the regenerative microspheres are dispersed in the three-dimensional network structure of the non-regenerative filling polymer materials to form a ball-in-ball structure, and the same ball-in-ball composite microsphere contains multiple regenerative microspheres. The present invention disperses the regenerative microspheres in the three-dimensional network structure of the non-regenerative filling polymer materials. On the one hand, due to the wrapping of the elastic non-regenerative filling polymer materials, the ball-in-ball composite microspheres also have good elasticity. After being injected into the subcutaneous tissue, it can provide volume support and play an immediate filling role; on the other hand, as the non-regenerative filling polymer materials that wrap the regenerative microspheres gradually degrade, the regenerative microspheres are gradually exposed and released, and the regenerative microspheres can stimulate fibroblasts in the skin to synthesize collagen, playing a role in long-term repair. The present invention can solve the problem that the existing subcutaneous fillers cannot achieve both filling effect and lasting effect.

[0035] 2. The injectable ball-in-ball composite microspheres for subcutaneous filling of the present invention have uniform morphology and good sphericity, and the coefficient of variation of the diameter does not exceed 5%, which can solve the problem that the existing injectable microspheres are not conducive to injection due to uneven size. Both the regenerative microspheres and the non-regenerative filling polymer materials are degradable, so the ball-in-ball composite microspheres are degradable in the body, which can avoid the long-term presence of permanent fillers in the body, leading to adverse reactions such as inflammatory nodules or granulomas.

[0036] 3. In the prior art, a double emulsion system is usually used to prepare core-shell microspheres, but the double emulsion system has the problems of difficult to grasp the interfacial tension, the difficulty of accurately controlling the size and number of internal droplets, and the limited number of internal droplets. The preparation method of injectable ball-in-ball composite microspheres for subcutaneous filling provided by the present invention disperses the pre-prepared regenerative microspheres into a non-regenerative filling polymer material solution, uses the obtained suspension as the internal phase fluid, and then prepares the ball-in-ball composite microspheres based on microfluidic technology. The method of the present invention has a simple process, low cost, can achieve continuous production, and the size of the prepared ball-in-ball composite microspheres is uniform. The size of the ball-in-ball composite microspheres can be accurately controlled by adjusting the flow rate of each phase fluid and the injection tube of the microfluidic device and the inner diameter of the collected cone mouth. The performance of the ball-in-ball composite microspheres can be adjusted by changing the content of the regenerative microspheres in the internal phase, and has the characteristics of good adjustability and controllability. The method of the present invention can solve the above-mentioned difficulties in the prior art of preparing ball-in-ball composite microspheres based on the double emulsion system. BRIEF DESCRIPTION OF THE DRAWINGS

[0037] Figure 1 The present invention is a schematic structural diagram of a primary capillary microfluidic device used in the present invention, wherein 1 is an injection tube, 2 is a connecting tube, and 3 is a collecting tube.

[0038] Figure 2 It is a diameter distribution diagram of the O / W emulsion droplets and PCL microspheres prepared in Example 1, wherein (a) represents the O / W emulsion droplets, and the illustration in the upper right corner is the optical image of the O / W emulsion droplets, and (b) represents the PCL microspheres, and the illustration in the upper right corner is the optical image of the PCL microspheres.

[0039] Figure 3 This is a scanning electron microscope image of the PCL microspheres prepared in Example 1.

[0040] Figure 4 is the diameter and diameter of the S / W / O emulsion droplets and HA / PCL ball-in-ball composite microspheres prepared in Example 1 CV The value changes with the external phase fluid flow rate (Q o ), where (a) shows the diameter of S / W / O emulsion droplets and HA / PCL ball-in-ball composite microspheres as a function of the external phase fluid flow rate (Qo ) changes, (b) is the curve of the change of external phase fluid flow rate (Q o The diameters of S / W / O emulsion droplets and HA / PCL sphere-in-sphere composite microspheres prepared under the conditions of CV value.

[0041] Figure 5 These are optical microscope photographs of the S / W / O emulsion and HA / PCL sphere-in-sphere composite microspheres prepared in Example 1 under the conditions of an external phase fluid flow rate of 40, 50, 60, and 70 μL / min, wherein figures a to d represent the S / W / O emulsion, and figures e to h represent the HA / PCL sphere-in-sphere composite microspheres.

[0042] Figure 6 is the diameter of the S / W / O emulsion droplets and HA / PCL ball-in-ball composite microspheres prepared in Example 2, and the diameter CV The value changes with the internal phase fluid flow rate (Q i ), where (a) shows the diameter of S / W / O emulsion droplets and HA / PCL ball-in-ball composite microspheres as the internal phase fluid flow rate (Q i ) changes, where (b) is the curve of the change of the internal phase fluid flow rate (Q i ) prepared under the conditions of S / W / O emulsion droplets and HA / PCL ball-in-ball composite microspheres CV value.

[0043] Figure 7 These are optical microscope photographs of the S / W / O emulsion and HA / PCL sphere-in-sphere composite microspheres prepared in Example 2 under the conditions of an internal phase fluid flow rate of 2, 3, 4, and 5 μL / min, wherein figures a to d represent the S / W / O emulsion, and figures e to h represent the HA / PCL sphere-in-sphere composite microspheres.

[0044] Figure 8 This is the swelling performance curve of HA / PCL microspheres.

[0045] Fig. 9 These are the elasticity curves and Young's modulus test results of HA microspheres and HA / PCL microspheres, where (a) is the elasticity curve and (b) is the Young's modulus.

[0046] Fig.10 is the result of blood compatibility test. The illustration in the upper right corner of the figure is the optical picture of each sample after centrifugation for 5 min. From left to right, they correspond to the positive control group, the negative control group, and the experimental groups with HA / PCL microsphere concentrations of 50, 100, 200, 500, and 1000 μg / mL.

[0047] Fig.11Figure 1 is a dynamic coagulation image and coagulation index measurement result of HA / PCL microspheres, wherein (a) is a dynamic coagulation image, and (b) is a coagulation index measurement result.

[0048] Fig.12 These are the results of cell viability tests after HA / PCL microspheres were co-cultured with L929 cells for 24, 48, and 72 h.

[0049] Fig.13 These are scanning electron micrographs of HA / PCL microspheres after being immersed in PBS buffer at 37°C for 1, 4, 8, and 12 weeks. The immersion times corresponding to images a to d are 1, 4, 8, and 12 weeks, respectively.

[0050] Fig.14 These are optical images of the emulsion and microspheres prepared in Example 8 when the PCL microsphere content in the internal phase fluid is 0, 0.2%, 0.6%, and 0.8%, wherein figures a to d represent the emulsion, and figures e to h represent the HA / PCL microspheres.

[0051] Fig.15 It is a diameter comparison diagram of the emulsion droplets and microspheres prepared in Example 8 when the PCL microsphere content is 0, 0.2%, 0.6%, and 0.8%, as well as a shrinkage rate comparison diagram of the microspheres, wherein (a) is a diameter comparison diagram, and (b) is a shrinkage rate comparison diagram.

[0052] Fig.16 It is a diameter distribution diagram of the S / W / O emulsion droplets and the Collagen / PLLA sphere-in-sphere composite microspheres prepared in Example 9, wherein (a) represents the S / W / O emulsion droplets, and the illustration in the upper right corner is an optical image of the S / W / O emulsion droplets, and (b) represents the Collagen / PLLA sphere-in-sphere composite microspheres, and the illustration in the upper right corner is an optical image of the Collagen / PLLA sphere-in-sphere composite microspheres.

[0053] Fig.17 This is a scanning electron microscope image of the PLLA microspheres prepared in Example 9.

[0054] Fig.18 This is a scanning electron microscope image of the Collagen / PLLA ball-in-ball composite microspheres prepared in Example 9. DETAILED DESCRIPTION

[0055] The following examples further illustrate the ball-in-ball microspheres for subcutaneous filling and the preparation method thereof provided by the present invention. It is necessary to point out that the following examples are only used to further illustrate the present invention and cannot be understood as limiting the scope of protection of the present invention. Those skilled in the art can make some non-essential improvements and adjustments to the present invention based on the above invention content, which still fall within the scope of protection of the present invention.

[0056] In the following embodiments, the microfluidic device used is a primary capillary microfluidic device, and its structural schematic diagram is shown in FIG. Figure 1 As shown, it includes an injection tube 1, a connecting tube 2 and a collecting tube 3, and is used in conjunction with a syringe pump. The injection tube 1 is made of a cylindrical glass capillary, the outer diameter of the circular tube section of which is 960 μm and the inner diameter of which is 500 μm. The tail of the cylindrical glass capillary is pulled into a cone shape by a needle puller, and then rolled and polished on sandpaper until the cone mouth has an inner diameter of about 40-60 μm (for preparing regenerative microspheres) or 200-300 μm (for preparing ball-in-ball microspheres). The collecting tube 3 is made of a cylindrical glass capillary, and both ends of the cylindrical glass capillary are polished flat, and the outer diameter of the collecting tube is 960 μm and the inner diameter is 200-300 μm (for preparing regenerative microspheres) or the outer diameter of the collecting tube is 960 μm and the inner diameter is 500-700 μm (for preparing ball-in-ball microspheres). The connecting tube 2 is a square glass tube, and both ends of the square glass tube are polished smooth and flat, and a square through hole is provided in the center thereof, and the through hole size is 1.0×1.0 mm. After being manufactured, the injection tube 1, the connecting tube 2 and the collecting tube 3 are ultrasonically cleaned in anhydrous ethanol and blown dry. The tail of the injection tube 1 is inserted into the head of the collecting tube 3 and connected through the connecting tube 2. The injection tube 1, the connecting tube 2 and the collecting tube 3 are coaxially arranged and fixed on the slide by AB glue. A steel pipe can be put on the injection tube 1, and the non-inlet end is fixed with AB glue to facilitate the connection of the injection pump. The inlet end of the connecting tube 2 is fixed with a flat needle by AB glue, and the non-inlet end of the connecting tube 2 is sealed by AB glue. Each flat needle is connected to the injection pump through a pipe fitting.

[0057] Example 1

[0058] In this embodiment, injectable ball-in-ball composite microspheres for subcutaneous filling, specifically hyaluronic acid (HA) / polycaprolactone (PCL) ball-in-ball composite microspheres, are prepared in the following steps:

[0059] (1) Preparation of PCL microspheres

[0060] ①Preparation of various phase fluids for preparing PCL microspheres

[0061] Preparation of the inner phase: PCL was dissolved in dichloromethane to obtain the inner phase; in the inner phase, the mass ratio of dichloromethane to PCL was 1:0.03.

[0062] Preparation of the external phase: Add polyvinyl alcohol (PVA) to deionized water, dissolve the PVA in an oil bath at 95°C to obtain the external phase; in the external phase, the mass ratio of deionized water to PVA is 1:0.05.

[0063] Prepare receiving solution: The receiving solution is the same as the external phase.

[0064] ② Preparation of PCL microspheres

[0065] Using structure such as Figure 1 The first-level capillary microfluidic device shown in the figure was prepared, and the cone inner diameter of the injection tube was 60 μm, and the inner diameter of the collection tube was 200 μm. The inner phase was injected into the injection tube of the microfluidic device by a syringe pump, and the outer phase was injected into the collection tube of the microfluidic device by a syringe pump. The flow rate of the inner phase was controlled to be 15 μL / min, and the flow rate of the outer phase was 80 μL / min. A monodispersed oil-in-water (O / W) emulsion was formed in the collection tube. The O / W emulsion was collected in a container containing a receiving liquid, and then stirred at a speed of 300 rpm for 2 h. The dichloromethane in the O / W emulsion droplets was completely volatilized, and the O / W emulsion droplets were solidified. The microspheres formed after solidification were separated from the receiving liquid, washed with deionized water for 3 to 5 times, and PCL microspheres were obtained, which were freeze-dried for storage.

[0066] Figure 2 It is the diameter distribution diagram of the O / W emulsion droplets and PCL microspheres prepared in this step, where (a) represents the O / W emulsion droplets, and the inset in the upper right corner is the optical image of the O / W emulsion droplets, and (b) represents the PCL microspheres, and the inset in the upper right corner is the optical image of the PCL microspheres. Figure 3 is a scanning electron microscope image of PCL microspheres prepared in this step. Figure 2~3 It can be seen that the coefficient of variation (Coefficient of variation, CV The PCL microspheres have uniform size and morphology, good monodispersity, good sphericity, and the diameters of the PCL microspheres are concentrated between 45.5 and 46 nm.

[0067] (2) Preparation of HA / PCL ball-in-ball composite microspheres

[0068] ①Preparation of various phase fluids for preparing HA / PCL ball-in-ball composite microspheres

[0069] Preparation of the inner phase fluid: dissolve hyaluronic acid (HA) and adipic acid dihydrazide (ADH) in a hydrochloric acid solution at pH = 4.5, add PCL microspheres, and mix thoroughly on a mixer to evenly disperse the PCL microspheres to obtain the inner phase fluid; in the inner phase fluid, the mass ratio of the hydrochloric acid solution, HA, ADH and PCL microspheres is 1: 0.025: 0.005: 0.005.

[0070] Preparation of external phase fluid: dissolving oil-soluble surfactant Span80 and activator 1-ethyl-(3-dimethylaminopropyl)carbodiimide (EDC) in n-octanol to obtain an external phase fluid; in the external phase fluid, the mass ratio of n-octanol, Span80 and EDC is 1: 0.08: 0.005.

[0071] Prepare collecting liquid: The collecting liquid is the same as the external phase fluid.

[0072] ② Preparation of HA / PCL ball-in-ball composite microspheres

[0073] Using structure such as Figure 1 The first-level capillary microfluidic device shown in the figure is prepared, and the cone inner diameter of the injection tube is 260 μm, and the inner diameter of the collection tube is 700 μm. The inner phase fluid is injected into the injection tube of the microfluidic device by a syringe pump, and the outer phase fluid is injected into the collection tube of the microfluidic device by a syringe pump, and a monodispersed oil-in-water-in-microsphere (S / W / O) emulsion is formed in the collection tube. The container containing the collection liquid is placed on a rotating table. The S / W / O emulsion is collected while the rotating table is rotating. The emulsion is allowed to stand for crosslinking at room temperature for 24 hours. The HA in the S / W / O emulsion undergoes a crosslinking reaction with ADH and solidifies. The solidified microspheres are washed with anhydrous ethanol and air-dried at room temperature to obtain HA / PCL-encapsulated composite microspheres.

[0074] In this step, a total of four groups of experiments were carried out. In each group of experiments, the flow rate of the inner phase was controlled to be 4 μL / min, and in the first to fourth groups of experiments, the flow rate of the outer phase fluid was controlled to be 40, 50, 60, and 70 μL / min, respectively.

[0075] Figure 4 is the diameter and diameter of the S / W / O emulsion droplets and HA / PCL ball-in-ball composite microspheres prepared in Example 1 CV The value changes with the external phase fluid flow rate (Q o ), where (a) shows the diameter of S / W / O emulsion droplets and HA / PCL ball-in-ball composite microspheres as a function of the external phase fluid flow rate (Q o ) changes, (b) is the curve of the change of external phase fluid flow rate (Q o The diameters of S / W / O emulsion droplets and HA / PCL sphere-in-sphere composite microspheres prepared under the conditions of CV Value. Figure 4 It can be seen that the droplet diameter of the S / W / O emulsion prepared in this embodiment is CV The values ​​are all less than 1%, and the diameter of HA / PCL ball-in-ball composite microspheres is CV The values ​​are all less than 3%, the size and morphology are uniform, and the monodispersity is good.

[0076] Figure 5 The optical microscope photos of the S / W / O emulsion and HA / PCL sphere-in-sphere composite microspheres prepared in Example 1 under the conditions of the external phase fluid flow rate of 40, 50, 60, and 70 μL / min, wherein the a-d images represent the S / W / O emulsion, and the e-h images represent the HA / PCL sphere-in-sphere composite microspheres. Figure 5It can be seen that both the S / W / O emulsion droplets and the HA / PCL sphere-in-sphere composite microspheres contain multiple PCL microspheres. The size and morphology of the S / W / O emulsion and the HA / PCL sphere-in-sphere composite microspheres are uniform and have good monodispersity.

[0077] Example 2

[0078] In this embodiment, HA / PCL ball-in-ball composite microspheres are prepared in the following steps:

[0079] The operation of this embodiment is basically the same as that of embodiment 1, except that, when preparing HA / PCL ball-in-ball composite microspheres in step (2), a total of four groups of experiments were performed, and the flow rate of the external phase fluid was controlled to be 80 μL / min in each group of experiments. The flow rates of the internal phase fluid were controlled to be 2, 3, 4, and 5 μL / min in the first to fourth groups of experiments, respectively.

[0080] Figure 6 is the diameter of the S / W / O emulsion droplets and HA / PCL ball-in-ball composite microspheres prepared in Example 2, and the diameter CV The value changes with the internal phase fluid flow rate (Q i ), where (a) shows the diameter of S / W / O emulsion droplets and HA / PCL ball-in-ball composite microspheres as a function of the internal phase fluid flow rate (Q i ) changes, where (b) is the curve of the change of the internal phase fluid flow rate (Q i ) prepared under the conditions of S / W / O emulsion droplets and HA / PCL ball-in-ball composite microspheres CV Value. Figure 6 It can be seen that the droplet diameter of the S / W / O emulsion prepared in this embodiment is CV The values ​​are all less than 1%, and the diameter of HA / PCL ball-in-ball composite microspheres is CV The values ​​are all less than 3%, the size and morphology are uniform, and the monodispersity is good.

[0081] Figure 7 The optical microscope photos of the S / W / O emulsion and HA / PCL sphere-in-sphere composite microspheres prepared in Example 2 under the condition that the flow rate of the internal phase fluid is 2, 3, 4, and 5 μL / min, wherein the a-d images represent the S / W / O emulsion, and the e-h images represent the HA / PCL sphere-in-sphere composite microspheres. Figure 7 It can be seen that both the S / W / O emulsion droplets and the HA / PCL sphere-in-sphere composite microspheres contain multiple PCL microspheres. The size and morphology of the S / W / O emulsion and the HA / PCL sphere-in-sphere composite microspheres are uniform and have good monodispersity.

[0082] Example 3

[0083] In this example, the swelling rate of the HA / PCL ball-in-ball composite microspheres (HA / PCL microspheres for short) prepared in Example 2 under the conditions of an external phase fluid flow rate of 80 μL / min and an internal phase fluid flow rate of 4 μL / min was tested as follows:

[0084] The dried HA / PCL microspheres were placed in a culture dish, and physiological saline was added to the culture dish. The dish was placed under an industrial microscope for observation. The swelling of the HA / PCL microspheres was observed at 0, 5, 10, 15, 20, 30, and 40 s after the addition of physiological saline. The swelling rate of the HA / PCL microspheres was calculated according to the following formula. The results are shown in Figure 2. Figure 8 shown.

[0085]

[0086] In the above formula, q is the swelling rate, v a is the volume of HA / PCL microspheres after swelling, v 0 is the initial volume of HA / PCL microspheres.

[0087] Depend on Figure 8 It can be seen that HA / PCL microspheres can reach swelling equilibrium after being immersed in physiological saline for about 10 s, and the swelling rate at swelling equilibrium is 361.91%.

[0088] Comparative Example 1

[0089] In this embodiment, hyaluronic acid (HA) microspheres are prepared in the following steps:

[0090] (1) Preparation of various phase fluids for preparing HA microspheres

[0091] Preparation of the internal phase fluid: dissolving HA and ADH in a hydrochloric acid solution at pH=4.5 to obtain the internal phase fluid; in the internal phase fluid, the mass ratio of the hydrochloric acid solution, HA and ADH is 1: 0.025: 0.005.

[0092] The external phase fluid was prepared by dissolving the oil-soluble surfactant Span80 and the activator EDC in n-octanol to obtain the external phase fluid; in the external phase fluid, the mass ratio of n-octanol, Span80 and EDC was 1: 0.08: 0.005.

[0093] Prepare collecting liquid: The collecting liquid is the same as the external phase fluid.

[0094] (2) Preparation of HA microspheres

[0095] The same primary capillary microfluidic device as in Example 1 was used for preparation. The internal phase fluid was injected into the injection tube of the microfluidic device by a syringe pump, and the external phase fluid was injected into the collection tube of the microfluidic device by a syringe pump. The flow rate of the external phase fluid was controlled to be 80 L / min, and the flow rate of the internal phase fluid was controlled to be 5 μL / min. A monodisperse water-in-oil (W / O) emulsion was formed in the collection tube. The container containing the collection liquid was placed on a rotating table. The W / O emulsion was collected while the rotating table was rotating. The emulsion was allowed to stand for crosslinking at room temperature for 24 h. The HA in the W / O emulsion reacted with ADH to crosslink and solidify. The solidified microspheres were washed with anhydrous ethanol and air-dried at room temperature to obtain HA microspheres.

[0096] The following tests are conducted on the elasticity curve and Young's modulus of the HA / PCL ball-in-ball composite microspheres (HA / PCL microspheres for short) prepared in step (2) of Example 2 under the conditions of an external phase fluid flow rate of 80 μL / min and an internal phase fluid flow rate of 4 μL / min, as well as the HA microspheres prepared in this comparative example.

[0097] HA microspheres and HA / PCL microspheres were placed in the liquid phase test tank, respectively, and tested on the mechanical strength tester using a 10 g sensor and a 580 μm probe. Both were tested ten times. The results are shown in the figure. Fig. 9 shown. Fig. 9 Figure 1 is the elasticity curve and Young's modulus test results of HA microspheres and HA / PCL microspheres, where (a) is the elasticity curve and (b) is the Young's modulus. HA in the figure represents HA microspheres and HA / PCL represents HA / PCL microspheres. Fig. 9 It can be seen that both HA microspheres and HA / PCL microspheres have good elasticity and have the potential for subcutaneous injection. Since PCL microspheres have strong rigidity and lack elasticity, the elasticity of HA / PCL microspheres is reduced relative to that of HA microspheres after the introduction of PCL microspheres. Since HA has good elasticity, wrapping PCL microspheres with HA can solve the problem that individual PCL microspheres lack elasticity.

[0098] Example 4

[0099] In this example, the blood compatibility of HA / PCL ball-in-ball composite microspheres (HA / PCL microspheres for short) prepared in step (2) of Example 2 under the conditions of an external phase fluid flow rate of 80 μL / min and an internal phase fluid flow rate of 4 μL / min was tested.

[0100] HA / PCL microspheres were prepared with physiological saline to prepare HA / PCL microsphere suspensions with concentrations of 50, 100, 200, 500, and 1000 μg / mL as experimental group samples. A negative control group and a positive control group were also set up. The sample used in the negative control group was physiological saline, and the sample used in the positive control group was deionized water.

[0101] For the experimental group, 4 mL of the experimental group sample of each concentration was placed in a 5 mL centrifuge tube, and 5 parallel samples were set for each concentration of the experimental group sample. For the negative control group, 4 mL of normal saline was placed in a 5 mL centrifuge tube, and 5 parallel samples were set. For the positive control group, 4 mL of deionized water was placed in a 5 mL centrifuge tube, and 5 parallel samples were set. Sodium citrate rat whole blood was diluted with normal saline at a ratio of 4: 5 (v / v), and 85 μL of diluted blood was added to each centrifuge tube, shaken and incubated at 37 °C for 1h. Centrifuge at 3000 rpm for 5 min, take the supernatant and add it to a 96-well plate, and use an enzyme reader to measure the absorbance value at a wavelength of 545 nm. The hemolysis rate (%) was calculated according to the following formula:

[0102]

[0103] In the above formula, A test , A negative and A positive are the absorbance values ​​of the experimental group, negative control group and positive control group, respectively.

[0104] Fig.10 The figure is the result of the blood compatibility test. The illustration in the upper right corner of the figure is the optical picture of each sample after centrifugation for 5 minutes. From left to right, they correspond to the positive control group, the negative control group, and the experimental group with HA / PCL microsphere concentrations of 50, 100, 200, 500, and 1000 μg / mL. From the optical picture, it can be seen that after the samples of the experimental group were centrifuged, the supernatant was clear and transparent, and the red blood cells were located at the bottom of the centrifuge tube, indicating that HA / PCL microspheres would not rupture the red blood cells. At the same time, the hemolysis rate of the experimental group was less than 1%, which was lower than the national standard limit for biomaterials and met the requirements of blood compatibility.

[0105] Example 5

[0106] In this example, the anticoagulant properties of HA / PCL sphere-in-sphere composite microspheres (HA / PCL microspheres for short) prepared in step (2) of Example 2 under the conditions of an external phase fluid flow rate of 80 μL / min and an internal phase fluid flow rate of 4 μL / min were tested.

[0107] HA / PCL microsphere suspensions with concentrations of 1000, 500, 200, 100, and 50 μg / mL were prepared with physiological saline as experimental group samples. A control group was also set up, and the sample used in the control group was physiological saline. 50 μL of the experimental group sample of each concentration was added to the 96-well plate, and 50 μL of the control group sample was added to the 96-well plate. Then 50 μL of anticoagulated rat whole blood was added to each well plate, and 5 μL of CaCl 2 (0.2 mol / L) was used to induce coagulation reaction. At 1, 3, 5, 7, and 10 min after the reaction, the HA / PCL microspheres were washed with saline and the coagulation status of each sample was recorded by taking photos.

[0108] HA / PCL microspheres were prepared with physiological saline to prepare HA / PCL microsphere suspensions with concentrations of 1000, 500, 200, 100, and 50 μg / mL as samples for the experimental group. At the same time, a control group was set up, and the sample used in the control group was physiological saline. For the experimental group, 50 μL of the experimental group sample of each concentration was added to a 5 mL centrifuge tube, and 5 parallel samples were set for each concentration of the experimental group sample. For the control group, 50 μL of physiological saline was added to a 5 mL centrifuge tube, and 5 parallel samples were set. 50 μL of anticoagulated rat whole blood was added to each centrifuge tube, and then 5 μL of CaCl was added. 2 (0.2 mol / L) to induce coagulation reaction. After incubation at 37 °C for 10, 20, 30, 40, and 50 min, 4 mL of deionized water was added to burst the red blood cells exposed on the surface but not yet coagulated to terminate the coagulation reaction. After another 10 min incubation, 100 μL of supernatant was drawn and added to the 96-well plate. The absorbance at a wavelength of 540 nm was measured with an ELISA reader, and the coagulation index [BCI (%)] was calculated according to the following formula:

[0109]

[0110] In the above formula, A test and A control are the absorbance values ​​of the experimental group and the control group, respectively.

[0111] Fig.11 The following are the dynamic coagulation images and coagulation index measurement results of HA / PCL microspheres, where (a) is the dynamic coagulation image and (b) is the coagulation index measurement result. It can be seen from the figure that the blood coagulation time of the experimental group and the control group is consistent, and the blood is basically completely coagulated at 7 minutes. The coagulation index of HA / PCL microspheres of various concentrations is above 90%, indicating that HA / PCL microspheres will not cause thrombosis.

[0112] Example 6

[0113] In this example, the HA / PCL sphere-in-sphere composite microspheres (HA / PCL microspheres for short) prepared in step (2) of Example 2 under the conditions of an external phase fluid flow rate of 80 μL / min and an internal phase fluid flow rate of 4 μL / min were co-cultured with mouse fibroblasts (L929 cells) to investigate the cytotoxicity of the HA / PCL microspheres, and the steps were as follows:

[0114] (1) Cell recovery: Take out the L929 cell cryovial from the liquid nitrogen tank and immediately place it in a 37°C water bath. Gently shake the cryovial in the water bath for 1-2 minutes to thaw. After thawing, sterilize the cryovial and move it to the clean bench to open the cryovial. Use a pipette to gently blow the cell suspension in the cryovial and add it to a centrifuge tube for later use. Add 3 mL of L929 cell culture medium to the centrifuge tube, centrifuge at 1000 rpm for 5 minutes to separate dead cells, and discard the supernatant. Add 9 mL of culture medium to the centrifuge tube, gently blow to resuspend the cells so that the cells are evenly dispersed, and then transfer all to the culture dish. Place the culture dish flat on the clean bench and shake it gently using the cross method to evenly distribute the cells in the culture dish. Then place it in a cell culture incubator at 37°C, 5% CO 2 The cells were cultured for 24 h to allow them to adhere.

[0115] (2) Cell passaging: Aspirate the culture medium in the culture dish and add PBS buffer to wash the cells 2-3 times. Add 1 mL of trypsin, digest for 30 seconds, then aspirate the trypsin and add 3 mL of culture medium to terminate the digestion. Aspirate the culture medium and blow the cells to gradually and completely detach the cells from the wall. After blowing evenly, disperse the cell suspension into several culture dishes and add the culture medium to each culture dish to 10 mL. Place the culture dish flat and shake it gently using the cross method to evenly distribute the cells, then place it in a cell culture incubator at 37°C and 5% CO. 2 The cells were cultured for 24 h to allow them to adhere.

[0116] (3) Plating: Aspirate the culture medium in the culture dish and add PBS buffer to wash the cells 2-3 times. Add 1 mL of trypsin, digest for 30 seconds, aspirate the trypsin, and add 3 mL of culture medium to terminate the digestion. Aspirate the culture medium and blow on the cells to gradually and completely detach the cells from the cell wall. Aspirate 10 μL of cell suspension and add it to the cell counting plate, calculate the cell density and add culture medium to the culture dish to make the final cell density about 2×10 4 / mL. Pipette the cell suspension and add 100 μL / well to three 96-well plates. Cover the plates with PBS buffer to prevent the culture medium from drying out. After plating, place the culture dishes in a cell culture incubator at 37°C and 5% CO. 2 The cells were cultured for 24 h under the conditions of

[0117] (4) The HA / PCL microspheres were sterilized by ultraviolet light, and the sterilized microspheres were washed by centrifugation with culture medium. The washed microspheres were prepared into dispersions with concentrations of 1000, 500, 200, 100, and 50 μg / mL with culture medium.

[0118] (5) Aspirate the culture medium in the 96-well plate, add 100 μL of dispersion solution of different concentrations to each well as the experimental group, and add 100 μL of culture medium as the control group. Set up 8 replicate wells for each group. After the addition of samples, place the 3-well plate in a cell culture incubator at 37 °C and 5% CO 2 The cells were cultured for 24, 48, and 72 h under the same conditions.

[0119] (6) Prepare 10% CCK-8 solution with CCK-8 culture medium. For the well plates that have been cultured for 24, 48, and 72 hours, aspirate the liquid in each well and add 100 μL of CCK-8 solution. Add CCK-8 solution to the blank well plate as a blank group. Place the well plate in an incubator at 37°C and 5% CO. 2 The cells were cultured for 3 h under the conditions of 450 nm and the absorbance at a wavelength of 450 nm was measured using an enzyme-labeled instrument. The cell viability (%) was calculated according to the following formula:

[0120]

[0121] In the above formula, A test , A contro l and A blank are the absorbance values ​​of the experimental group, control group and blank group, respectively.

[0122] Fig.12 This is the cell viability test result after 24, 48, and 72 h of co-culture of HA / PCL microspheres and L929 cells. It can be seen from the figure that the cell viability of L929 cells is greater than 85% after 24, 48, and 72 h of co-culture with HA / PCL microspheres of various concentrations, indicating that HA / PCL microspheres have good cell compatibility and have no obvious effect on cell viability.

[0123] Example 7

[0124] In this example, the in vitro stability of HA / PCL ball-in-ball composite microspheres (HA / PCL microspheres for short) prepared in step (2) of Example 2 under the conditions of an external phase fluid flow rate of 80 μL / min and an internal phase fluid flow rate of 4 μL / min was tested. The HA / PCL microspheres were immersed in PBS buffer at 37°C, and a small amount of microspheres were taken out after 1, 4, 8, and 12 weeks. After natural sedimentation, the supernatant was aspirated, washed with deionized water, and air-dried and then scanned electron microscopy images were taken. The results are shown in FIG. Fig.13 As shown, the immersion times corresponding to Figures a~d are 1, 4, 8, and 12 weeks respectively.

[0125] Depend on Fig.13 It can be seen that the HA / PCL microspheres hardly degraded in the first week and had a very smooth surface. They began to degrade from the fourth week. As the degradation progressed, the external HA began to tear in the eighth week. By the twelfth week, most of the HA was degraded, and the internal PCL microspheres were exposed and released. A small amount of degradation was observed on the surface of the PCL microspheres.

[0126] As a filling material, HA has good viscoelasticity and excellent biocompatibility, but HA has a fast degradation rate and poor mechanical strength; PCL microspheres have the effect of stimulating collagen regeneration, but have poor elasticity. In combination with Examples 3 and 7, it can be seen that the present invention disperses PCL microspheres in the elastic three-dimensional network structure of HA to form ball-in-ball composite microspheres, which not only gives the composite microspheres the ability to stimulate collagen production, but also gives the composite microspheres good compressibility and resilience. The good compressibility and resilience of the composite microspheres are conducive to avoiding blockage during the injection process. After being injected into the subcutaneous tissue, the ball-in-ball composite microspheres first provide a supporting volume to fill skin depressions or wrinkles. As HA gradually degrades, the PCL microspheres are gradually exposed and released, playing a role in stimulating fibroblasts in the skin to synthesize new collagen.

[0127] Example 8

[0128] In this embodiment, HA / PCL ball-in-ball composite microspheres are prepared in the following steps:

[0129] (1) Preparation of PCL microspheres

[0130] The procedure for preparing PCL microspheres was the same as step (1) of Example 1.

[0131] (2) Preparation of ball-in-ball composite microspheres

[0132] ①Preparation of various phase fluids for preparing ball-in-ball composite microspheres

[0133] The first to third groups of inward fluids were prepared by dissolving HA and ADH in a hydrochloric acid solution of pH 4.5, adding the PCL microspheres prepared in step (1), and mixing them thoroughly on a mixer to uniformly disperse the PCL microspheres to obtain an inner phase fluid; in the first to third groups of inner phase fluids, the mass ratios of the hydrochloric acid solution, HA, ADH and PCL microspheres were 1: 0.025: 0.005: 0.002, 1: 0.025: 0.005: 0.006, and 1: 0.025: 0.005: 0.008, respectively;

[0134] The fourth group of internal phase fluid was prepared by dissolving HA and ADH in a hydrochloric acid solution of pH=4.5 and mixing them thoroughly on a mixer to obtain an internal phase fluid, in which the mass ratios of the hydrochloric acid solution, HA and ADH were 1: 0.025: 0.005, respectively.

[0135] The external phase fluid was prepared by dissolving the oil-soluble surfactant Span80 and the activator EDC in n-octanol to obtain the external phase fluid; in the external phase fluid, the mass ratio of n-octanol, Span80 and EDC was 1: 0.08: 0.005.

[0136] Prepare collecting liquid: The collecting liquid is the same as the external phase fluid.

[0137] ② Preparation of ball-in-ball composite microspheres

[0138] The same primary capillary microfluidic device as in Example 1 was used for preparation.

[0139] The first to third groups of internal phase fluids are respectively injected into the injection tubes of the microfluidic device by injection pumps, and the external phase fluid is injected into the collecting tube of the microfluidic device by injection pumps to form a monodisperse S / W / O emulsion in the collecting tube. The container containing the collected liquid is placed on a rotating table to collect the S / W / O emulsion while the rotating table is rotating. The emulsion is allowed to stand for crosslinking at room temperature for 24 hours. The HA in the S / W / O emulsion undergoes a crosslinking reaction with ADH to solidify. The solidified microspheres are washed with anhydrous ethanol and air-dried at room temperature to obtain HA / PCL ball-in-ball composite microspheres.

[0140] The fourth group of internal phase fluid was injected into the injection tube of the microfluidic device by a syringe pump, and the external phase fluid was injected into the collecting tube of the microfluidic device by a syringe pump to form a monodisperse W / O emulsion in the collecting tube. The container containing the collected liquid was placed on a rotating table to collect the W / O emulsion while the rotating table was rotating. The emulsion was allowed to stand for crosslinking at room temperature for 24 h. The HA in the W / O emulsion reacted with ADH to undergo a crosslinking reaction and solidified. The solidified microspheres were washed with anhydrous ethanol and air-dried at room temperature to obtain HA microspheres.

[0141] During the above preparation process, the flow rate of the inner phase fluid was controlled at 4 μL / min, and the flow rate of the outer phase fluid was controlled at 70 μL / min.

[0142] An industrial microscope was used to record the morphology of S / W / O emulsion droplets or W / O emulsion droplets, as well as HA / PCL ball-in-ball composite microspheres or HA microspheres. The diameter was measured using the matching measurement software, and the shrinkage rate (%) was calculated according to the following formula:

[0143]

[0144] In the above formula, D dis the average diameter of the emulsion droplets, D m is the average diameter of the microspheres.

[0145] Fig.14 These are optical images of the emulsion and microspheres prepared in Example 8 when the PCL microsphere content in the internal phase fluid is 0, 0.2%, 0.6%, and 0.8%, wherein the a-d images represent the emulsion, and the e-h images represent the HA / PCL microspheres. Fig.14 It can be seen that the morphology and size of the emulsion droplets and microspheres prepared in this example are uniform. Fig.15 The following are the diameter comparison diagrams of the emulsion droplets and microspheres prepared in Example 8 when the PCL microsphere content is 0, 0.2%, 0.6%, and 0.8%, as well as the shrinkage rate comparison diagram of the microspheres, wherein (a) is the diameter comparison diagram and (b) is the shrinkage rate comparison diagram. Fig.15 It can be seen that with the increase of PCL microsphere content in the internal phase fluid, the diameter of the emulsion droplets remains almost unchanged, but the diameter of the microspheres gradually increases and the shrinkage rate gradually decreases. This is because the content of PCL microspheres has no obvious effect on the diameter of the emulsion droplets, but when the emulsion droplets solidify, their diameter will shrink significantly. The more PCL microspheres contained in the emulsion, the larger the diameter of the ball-in-ball composite microspheres and the smaller the shrinkage rate.

[0146] Example 9

[0147] In this embodiment, collagen (Collagen) / poly-L-lactic acid (PLLA) ball-in-ball composite microspheres are prepared in the following steps:

[0148] (1) Preparation of PLLA microspheres

[0149] ①Preparation of each phase fluid for preparing PLLA microspheres

[0150] Preparation of the inner phase: dissolving poly (L-lactic acid) (PLLA) in dichloromethane to obtain the inner phase; in the inner phase, the mass ratio of dichloromethane to PLLA is 1:0.05.

[0151] Preparation of the external phase: Add polyvinyl alcohol (PVA) to deionized water, dissolve the PVA in an oil bath at 95° C. to obtain the external phase; in the external phase, the mass ratio of deionized water to PVA is 1:0.05.

[0152] Prepare receiving solution: The receiving solution is the same as the external phase.

[0153] ② Preparation of PLLA microspheres

[0154] The same primary capillary microfluidic device as in Example 1 was used for preparation. The inner phase was injected into the injection tube of the microfluidic device by a syringe pump, and the outer phase was injected into the collection tube of the microfluidic device by a syringe pump. The flow rate of the inner phase was controlled to be 10 μL / min, and the flow rate of the outer phase was controlled to be 150 μL / min. A monodispersed O / W emulsion was formed in the collection tube, and the O / W emulsion was collected in a container containing a receiving liquid, and then stirred at a speed of 300 rpm for 2 h. The dichloromethane in the O / W emulsion droplets was completely volatilized, and the O / W emulsion droplets were solidified. The solidified microspheres were separated from the receiving liquid, washed with deionized water for 3 to 5 times, and PLLA microspheres were obtained, which were freeze-dried for storage.

[0155] (2) Preparation of Collagen / PLLA ball-in-ball composite microspheres

[0156] ①Preparation of various phase fluids for preparing ball-in-ball composite microspheres

[0157] Preparation of inner phase fluid: Dissolve collagen and 50% glutaraldehyde aqueous solution in 1% acetic acid aqueous solution by mass, add PLLA microspheres, and mix thoroughly on a mixer to evenly disperse the PLLA microspheres to obtain an inner phase fluid; in the inner phase fluid, the mass ratio of acetic acid solution, collagen, glutaraldehyde and PCL microspheres is 1: 0.05: 0.002: 0.005.

[0158] Preparation of external phase fluid: dissolving oil-soluble surfactant polyglyceryl ricinoleate (PGPR) and activator EDC in soybean oil to obtain external phase fluid; in the external phase fluid, the mass ratio of soybean oil, PGPR and EDC is 1: 0.04: 0.001.

[0159] Prepare collecting liquid: The collecting liquid is the same as the external phase fluid.

[0160] ② Preparation of Collagen / PLLA ball-in-ball composite microspheres

[0161] Using structure such as Figure 1The first-level capillary microfluidic device shown in the figure is prepared, and the cone inner diameter of the injection tube is 280 μm, and the inner diameter of the receiving tube is 700 μm. The inner phase fluid is injected into the injection tube of the microfluidic device by a syringe pump, and the outer phase fluid is injected into the collection tube of the microfluidic device by a syringe pump. The flow rate of the inner phase fluid is controlled to be 10 μL / min, and the flow rate of the outer phase fluid is 100 μL / min. A monodisperse S / W / O emulsion is formed in the collection tube. The container containing the collection liquid is placed on a rotating table. The S / W / O emulsion is collected while the rotating table is rotating. The S / W / O emulsion is allowed to stand for crosslinking at room temperature for 48 hours. The collagen in the S / W / O emulsion undergoes a crosslinking reaction with glutaraldehyde and solidifies. The solidified microspheres are first washed with isopropanol, then washed with water, and freeze-dried to obtain Collagen / PLLA ball-in-ball composite microspheres.

[0162] Fig.16 The diameter distribution diagram of the S / W / O emulsion droplets and the Collagen / PLLA sphere-in-sphere composite microspheres prepared in Example 9, wherein (a) represents the S / W / O emulsion droplets, and the illustration in the upper right corner is an optical image of the S / W / O emulsion droplets, and (b) represents the Collagen / PLLA sphere-in-sphere composite microspheres, and the illustration in the upper right corner is an optical image of the Collagen / PLLA sphere-in-sphere composite microspheres. Fig.16 It can be seen that the size and morphology of the S / W / O emulsion droplets and the Collagen / PLLA ball-in-ball composite microspheres prepared in this example are uniform. CV The values ​​are all less than 3%.

[0163] Fig.17 , Fig.18 The following are scanning electron microscope images of the PLLA microspheres and the Collagen / PLLA microsphere-in-sphere composite microspheres prepared in Example 9. Figures 17 and 18 It can be seen that the PLLA microspheres are uniform in size and have good sphericity, with a diameter of about 50 μm. The surface of the Collagen / PLLA ball-in-ball composite microspheres is smooth and densely cross-linked, and the edges of the PLLA microspheres encapsulated inside are clearly visible.

[0164] Example 10

[0165] In this embodiment, HA / PCL ball-in-ball composite microspheres are prepared in the following steps:

[0166] (1) Preparation of PCL microspheres

[0167] The procedure for preparing PCL microspheres was the same as step (1) of Example 1.

[0168] (2) Preparation of ball-in-ball composite microspheres

[0169] ①Preparation of various phase fluids for preparing HA / PCL ball-in-ball composite microspheres

[0170] Preparation of internal phase fluid: Dissolve HA and 1,4-butanediol glycidyl ether (BDDE) in a sodium hydroxide solution with a pH of 11, add PCL microspheres, and mix thoroughly on a mixer to evenly disperse the PCL microspheres to obtain an internal phase fluid. In the internal phase fluid, the mass ratio of sodium hydroxide solution, HA, BDDE and PCL microspheres is 1: 0.02: 0.004: 0.005.

[0171] Preparation of external phase fluid: dissolving oil-soluble surfactant T154 in n-octanol to obtain external phase fluid; in the external phase fluid, the mass ratio of T154 to n-octanol is 1:0.04.

[0172] Prepare collecting liquid: The collecting liquid is the same as the external phase fluid.

[0173] ② Preparation of HA / PCL ball-in-ball composite microspheres

[0174] The same primary capillary microfluidic device as in Example 1 was used for preparation. The inner phase fluid was injected into the injection tube of the microfluidic device by a syringe pump, and the outer phase fluid was injected into the collection tube of the microfluidic device by a syringe pump. The flow rate of the outer phase fluid was controlled to be 5 μL / min and the flow rate of the inner phase fluid was controlled to be 75 μL / min. A monodisperse S / W / O emulsion was formed in the collection tube. The container containing the collected liquid was placed on a rotating table. The S / W / O emulsion was collected while the rotating table was rotating. The collected liquid was placed at room temperature for 24 h. The HA in the S / W / O emulsion was cross-linked and solidified. The solidified microspheres were washed with isopropanol and air-dried at room temperature to obtain HA / PCL ball-in-ball composite microspheres.

[0175] Embodiment 11

[0176] In this embodiment, methacrylylated hyaluronic acid (HAMA) / PCL ball-in-ball composite microspheres are prepared in the following steps:

[0177] (1) Preparation of PCL microspheres

[0178] The procedure for preparing PCL microspheres was the same as step (1) of Example 1.

[0179] (2) Preparation of HAMA / PCL ball-in-ball composite microspheres

[0180] ① Preparation of various phase fluids for preparing HAMA / PCL ball-in-ball composite microspheres

[0181] Preparation of the internal phase fluid: Dissolve HAMA and the photoinitiator LAP in deionized water, add PCL microspheres, and mix thoroughly on a mixer to evenly disperse the PCL microspheres to obtain the internal phase fluid; in the internal phase fluid, the mass ratio of deionized water, HAMA, LAP and PCL microspheres is 1: 0.03: 0.0025: 0.006.

[0182] Preparation of external phase fluid: dissolving oil-soluble surfactant T154 in soybean oil to obtain external phase fluid; in the external phase fluid, the mass ratio of T154 to soybean oil is 1:0.04.

[0183] Prepare collecting liquid: The collecting liquid is the same as the external phase fluid.

[0184] ② Preparation of ball-in-ball composite microspheres

[0185] The same primary capillary microfluidic device as in Example 1 was used for preparation. The inner phase fluid was injected into the injection tube of the microfluidic device by a syringe pump, and the outer phase fluid was injected into the collection tube of the microfluidic device by a syringe pump. The flow rate of the outer phase fluid was controlled to be 4 μL / min and the flow rate of the inner phase fluid was controlled to be 80 μL / min. A monodisperse S / W / O emulsion was formed in the collection tube. The container containing the collection liquid was placed on a rotating table. The S / W / O emulsion was collected while the rotating table was rotating. Then, it was placed under an ultraviolet lamp for 3 minutes. The HAMA in the S / W / O emulsion was cross-linked and solidified under the action of the photoinitiator. The solidified microspheres were washed with isopropanol and air-dried at room temperature to obtain HAMA / PCL ball-in-ball composite microspheres.

[0186] It can be seen from the above embodiments that the ball-in-ball composite microspheres prepared by the method of the present invention have uniform size and morphology, good monodispersity; can quickly reach swelling equilibrium in physiological saline; good elastic properties, and have the potential for subcutaneous injection; the hemolysis rate is less than 1%, which is lower than the national standard limit of biomaterials and meets the requirements of blood compatibility; the coagulation index is above 90%, and will not cause thrombosis; it has good cell compatibility and has no obvious effect on cell vitality; the non-regenerative filling polymer material will degrade before the regenerative microspheres, and the regenerative microspheres will be exposed and released as the non-regenerative filling polymer material gradually degrades. Based on the above characteristics, the ball-in-ball composite microspheres of the present invention can be used as an injectable subcutaneous filler to improve the repair effect of soft tissue volume loss and wrinkles and folds.

[0187] The above embodiments are only some embodiments of the present invention and are not intended to limit the present invention. Ordinary technicians in the field can make non-essential adjustments such as equivalent replacement or change according to the technical concept and technical solution of the present invention. All non-essential adjustments should be included in the protection scope of the present invention.

Claims

1. Injectable ball-in-ball composite microspheres for subcutaneous filling, characterized in that: The ball-in-ball composite microspheres are composed of monodisperse regenerative microspheres and non-regenerative filling polymer materials, wherein the non-regenerative filling polymer materials are formed by crosslinking the non-regenerative polymers with a crosslinking agent or by crosslinking the non-regenerative polymers with light, the regenerative microspheres can stimulate fibroblasts in the skin to synthesize collagen, the regenerative microspheres are dispersed in the three-dimensional network structure of the non-regenerative filling polymer materials to form ball-in-ball composite microspheres, and the same ball-in-ball composite microsphere contains a plurality of regenerative microspheres; the particle size of the ball-in-ball composite microspheres is 100-300 μm, and the coefficient of variation of the diameter of the ball-in-ball composite microspheres does not exceed 5%, the particle size of the regenerative microspheres is 40-60 μm, and the coefficient of variation of the diameter of the regenerative microspheres does not exceed 5%; the non-regenerative polymer is hyaluronic acid, methacryloyl hyaluronic acid or collagen; The preparation method of the ball-in-ball composite microsphere comprises the following steps: (1) Preparation of internal phase fluid, external phase fluid and collection fluid Preparation of internal phase fluid: dissolving non-regenerative polymer and cross-linking agent in aqueous solvent, adding monodisperse regenerative microspheres, fully dispersing to obtain internal phase fluid, wherein the mass ratio of aqueous solvent, non-regenerative polymer, cross-linking agent and regenerative microspheres in the internal phase fluid is 1: (0.02-0.05): (0.002-0.005): (0.002-0.008); or, dissolving non-regenerative polymer and photoinitiator in aqueous solvent, adding monodisperse regenerative microspheres, fully dispersing to obtain internal phase fluid, wherein the mass ratio of aqueous solvent, photoinitiator and regenerative microspheres in the internal phase fluid is 1: (0.001-0.003): (0.002-0.008); Prepare the external phase fluid: dissolve the oil-soluble surfactant in the oily solvent to obtain the external phase fluid, in which the mass ratio of the oily solvent to the oil-soluble surfactant is 1:(0.04-0.08); or, dissolve the oil-soluble surfactant and the activator in the oily solvent to obtain the external phase fluid, in which the mass ratio of the oily solvent to the oil-soluble surfactant and the activator is 1:(0.04-0.08):(0.001-0.005); Prepare the collecting fluid: the collecting fluid is the same as the external phase fluid; (2) Preparation of ball-in-ball composite microspheres Injecting the inner phase fluid into the injection tube of the microfluidic device, injecting the outer phase fluid into the collection tube of the microfluidic device, controlling the volume flow ratio of the outer phase fluid to the inner phase fluid to be (10-40):1, forming a monodisperse oil-in-water-in-microsphere emulsion in the collection tube, collecting the oil-in-water-in-microsphere emulsion with a collecting fluid, applying conditions to cause a cross-linking reaction of the non-regenerative polymer in the oil-in-water-in-microsphere emulsion to solidify the oil-in-water-in-microsphere emulsion, washing the solidified microspheres with anhydrous ethanol, and drying to obtain ball-in-ball composite microspheres; The microfluidic device in this step is a primary capillary microfluidic device, in which the injection tube and the collecting tube of the microfluidic device are coaxially arranged, the inner diameter of the injection tube outlet is 200-300 μm, and the inner diameter of the collecting tube is 500-700 μm.

2. The injectable ball-in-ball composite microsphere for subcutaneous filling according to claim 1, characterized in that: The material of the regenerative microspheres is polycaprolactone or poly-L-lactic acid.

3. The injectable ball-in-ball composite microsphere for subcutaneous filling according to claim 1 or 2, characterized in that: In the ball-in-ball composite microspheres, the mass ratio of the regenerated microspheres to the non-regenerated filling polymer material is 1:(4-8).

4. The injectable ball-in-ball composite microsphere for subcutaneous filling according to claim 1 or 2, characterized in that: When the non-renewable filling polymer material is formed by cross-linking the non-renewable polymer via a cross-linking agent, the non-renewable filling polymer material is formed by cross-linking the non-renewable polymer and the cross-linking agent in a mass ratio of 1: (0.005 ~0.02).

5. The injectable ball-in-ball composite microsphere for subcutaneous filling according to claim 1, characterized in that: The cross-linking agent is adipic acid dihydrazide, 1,4-butanediol diglycidyl ether or glutaraldehyde; the oil-soluble surfactant is polyricinoleic acid glyceride, oleic acid dianhydrous ethanolamide, T154, Span20, Span40, Span60, Span80 or Tween85.

6. The injectable ball-in-ball composite microsphere for subcutaneous filling according to claim 1, characterized in that: The cross-linking reaction time in step (2) is controlled to be 24 to 48 h.

Citation Information

Patent Citations

  • Method for preparing microspheres in oil-in-nanosuspension and solid-in-oil mode

    CN102895191A

  • Mixed gel of polylactic acid microspheres and cross-linked hyaluronic acid for injection and preparation method of mixed gel

    CN104258470A

  • Visual monodisperse embolism microsphere with internal radiotherapy performance and preparation method of visual monodisperse embolism microsphere

    CN113198041A

  • Gradient injection containing mixed polymer microspheres

    CN114099771A

  • Skin filling agent containing macromolecular double-microsphere system and preparation method of skin filling agent

    CN116510090A